Regina Hodits

Managing Partner at Wellington Partners GmbH

Regina Hodits

Regina Hodits

Managing Partner at Wellington Partners GmbH

Overview
Career Highlights

Wellington Partners GmbH

RelSci Relationships

2213

Number of Boards

26

Birthday

12/1969

Age

51

Contact Data
Trying to get in touch with Regina Hodits? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Regina Hodits likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Middle Peak Medical, Inc.

Relationship likelihood: Strong

Executive Vice President-Life Sciences at Gimv NV

Relationship likelihood: Strong

Director at U3 Pharma AG

Relationship likelihood: Strong

Partner at SR One Ltd.

Relationship likelihood: Strong

Co-Founder at Ayoxxa Biosystems GmbH

Relationship likelihood: Strong

General Partner, Legal Counsel at Wellington Partners GmbH

Relationship likelihood: Strong

Co-Founder at Rigontec GmbH

Relationship likelihood: Strong

Executive Chairman at Atopix Therapeutics Ltd.

Relationship likelihood: Strong

Chief Executive Officer at Ayoxxa Biosystems GmbH

Relationship likelihood: Strong

Chief Executive Officer at GlaxoSmithKline Plc

Relationship likelihood: Strong

Paths to Regina Hodits
Potential Connections via
Relationship Science
You
Regina Hodits
Managing Partner at Wellington Partners GmbH
Education
Master of Science

The Vienna University of Technology (German: Technische Universität Wien) is one of the major universities in Vienna, the capital of Austria. Founded in 1815 as the "Imperial-Royal Polytechnic Institute" (k. k. Polytechnisches Institut), it currently has about 26,200 students (19% foreign students/30% women), eight faculties and about 4,000 staff members (1,800 academics). The university's teaching and research is focused on engineering and natural sciences.

MS Chemical Engineering

Vienna University of Technology is a research university specializing in the STEM fields.

Career History
Managing Partner
2010 - Current

WP specializes in the life sciences and technology sectors. They favor industries such as therapeutics, medical technology, diagnostics, digital media, distinctive electronics technology and software. The firm invests venture capital in young companies, including seed, startups, early-stage and expanding businesses. WP is a pan-European investor focused on northern, western and central Europe. The firm also marginally invests in the US. They follow a hands-on approach to promoting the growth of their portfolio companies. They build up management teams and provide business support without interfering in day-to-day operations.WP seeks to invest in companies with focused goals, significant international sales potential in high-growth markets, and whose products address the needs of customers likely to pay a premium. They aim to identify businesses with global market leadership potential, that are poised to create, embrace or exploit global technology trends.WP invests EUR 500 thousand to 20 million in the form of direct equity, and generally acquires minority stakes.

Board of Directors, Member
Current

Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded on September 1, 2009 by Erich Tauber and is headquartered in Vienna, Austria.

Board of Directors, Member
Current

Atopix Therapeutics Ltd. develops medicines to treat atopic dermatitis and severe asthma. The firm also assess the safety and pharmacokinetic profile of its back-up molecule ATX2417 in a phase I study. The company was incorporated on October 10, 2012 and is headquartered in Abingdon, the United Kingdom.

Boards & Committees
Director
Current

Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany.

Director
Current

Middle Peak Medical, Inc. develops implants for treatment of mitral valve disease. Its technology has application in both percutaneous catheter-based intervention and in minimally invasive or open-heart cardiac surgery. The company was founded by Michael D. Lesh and Alexander Khairkhahan in 2011 and is headquartered in Palo Alto, CA.

Director
Current

Sapiens Steering Brain Stimulation GmbH develops and markets steering deep brain stimulation (DBS) solutions. The firm specializes in the research, design, and delivery of medical solutions to patients suffering from degenerative or functional brain disorders, such as Parkinson’s disease and dystonia. Its product offerings encompass micro-fabricated probes, neurostimulators, and the SureSuite technology, which act as a unified surgical procedure platform. Its SurePlan, SurePlace, and SureTune products provide an integrated and image-based solution for planning and programming an optimal DBS treatment. The company was founded by Sjaak Deckers, Michel Decré and Hubert Martens in 2011 and is headquartered in Munich, Germany.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Regina Hodits. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Regina Hodits's profile does not indicate a business or promotional relationship of any kind between RelSci and Regina Hodits.